VIPR2 and chronic obstructive pulmonary disease: Hence, the effects of VPAC2 agonists in COPD may exceed their demonstrated dual bronchodilatory and anti-inflammatory potential, in that they concomitantly exert vasodilatory effects in the pulmonary circulation.